Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Trikafta
|
| gptkbp:activities |
CFTR modulator
|
| gptkbp:approves |
gptkb:2019
gptkb:FDA |
| gptkbp:brand |
Kaftrio
|
| gptkbp:can_be_used_with |
gptkb:ivacaftor
gptkb:tezacaftor |
| gptkbp:clinical_trial |
Phase 3
ongoing studies treatment of cystic fibrosis |
| gptkbp:composed_of |
synthetic organic compound
|
| gptkbp:contraindication |
severe liver impairment
hypersensitivity to elexacaftor |
| gptkbp:developed_by |
gptkb:Vertex_Pharmaceuticals
|
| gptkbp:dissolved |
soluble in DMSO
soluble in ethanol slightly soluble in water |
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:excretion |
urine
feces |
| gptkbp:future_plans |
exploring long-term effects
investigating new formulations |
| gptkbp:healthcare |
necessary for optimal use
|
| https://www.w3.org/2000/01/rdf-schema#label |
elexacaftor
|
| gptkbp:indication |
CFTR mutation-positive cystic fibrosis
|
| gptkbp:ingredients |
C22 H26 F2 N4 O3 S
|
| gptkbp:interacts_with |
CY P3 A inducers
CY P3 A inhibitors |
| gptkbp:invention |
patented
|
| gptkbp:is_atype_of |
R07 AX
|
| gptkbp:is_used_for |
gptkb:cystic_fibrosis
|
| gptkbp:manager |
oral
|
| gptkbp:market |
global markets
|
| gptkbp:marketed_as |
gptkb:Trikafta
|
| gptkbp:pharmacokinetics |
highly protein-bound
metabolized by liver |
| gptkbp:population |
adults and children over 12
|
| gptkbp:price |
high cost of therapy
|
| gptkbp:provides_information_on |
taken with food
included in treatment guidelines for cystic fibrosis |
| gptkbp:receives_funding_from |
supported by government and private grants
|
| gptkbp:regulatory_compliance |
approved for use in multiple countries
|
| gptkbp:research_areas |
multiple clinical research centers
|
| gptkbp:research_focus |
CFTR modulation
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:scholarships |
available for financial assistance
|
| gptkbp:side_effect |
fatigue
headache nausea abdominal pain diarrhea rash elevated liver enzymes nasopharyngitis respiratory symptoms upper respiratory tract infection |
| gptkbp:treatment |
tezacaftor/ivacaftor
|
| gptkbp:type_of |
1394640-13-0
|
| gptkbp:type_of_care |
important for treatment efficacy
|
| gptkbp:type_of_insurance |
varies by plan
|
| gptkbp:weight |
438.53 g/mol
|